By Colin Kellaher
Bluebird bio has struck a deal to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
Bluebird on Friday said its investors will receive an initial $3 a share in cash under the deal, along with contingent value rights worth $6.84 a share that would be triggered if the gene-therapy company's current product portfolio achieves $600 million in sales in any trailing 12-month period by the end of 2027.
The potential total value of up to $9.84 a share represents a nearly 40% premium to Thursday's closing price of $7.04 for the Somerville, Mass., company.
The deal is slated to close in the first half of the year.
Trading in shares of bluebird was halted premarket on Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 21, 2025 07:59 ET (12:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。